The FDA began integration of generative AI across all its centers, a project that should be completed by the end of June. Newly appointed chief AI officer, Jeremy Walsh, and Office of Strategic Programs at CDER, Sridhar Mantha, intend to accelerate the review for new therapies. Walsh also began talks with OpenAI about developing a ChatGPT offshoot for the FDA. AI integration aligns with President Trump’s push to position the U.S. as an AI hub with development of the multi-billion-dollar Stargate Project.
Please see full publication below for more information.
